More about

Thyroid Cancer

News
October 22, 2023
2 min read
Save

Selpercatinib improves outcomes in RET-mutant medullary thyroid cancer

Selpercatinib improves outcomes in <i>RET</i>-mutant medullary thyroid cancer

MADRID — Selpercatinib improved outcomes compared with cabozantinib or vandetanib for treatment of RET-mutant medullary thyroid cancer, according to randomized phase 3 study results presented at ESMO Congress.

News
September 27, 2023
2 min read
Save

Secondary solid tumors common among those who developed thyroid cancer after Chernobyl

Secondary solid tumors common among those who developed thyroid cancer after Chernobyl

Men and women who developed thyroid cancer after the Chernobyl nuclear disaster had a significantly higher incidence of secondary solid tumors, according to study results published in JAMA Network Open.

News
September 15, 2023
3 min read
Save

Lack of knowledge, distress are barriers to active surveillance for thyroid cancer

Lack of knowledge, distress are barriers to active surveillance for thyroid cancer

Adults with low-risk thyroid cancer cite concerns about adverse outcomes, psychological distress and a negative response to their diagnosis as reasons they opted for surgery over active surveillance, according to study findings.

News
August 24, 2023
3 min read
Save

Thyroid cancer surgeries at very low-volume centers increase odds for complications

Thyroid cancer surgeries at very low-volume centers increase odds for complications

Adults who undergo thyroid cancer surgery at clinics performing five or fewer operations per year are more likely to have recurrence or persistent disease than those attending higher-volume centers, according to study data.

News
August 24, 2023
1 min read
Save

Selpercatinib prolongs PFS in RET-mutant medullary thyroid cancer

Selpercatinib prolongs PFS in <i>RET</i>-mutant medullary thyroid cancer

Selpercatinib extended PFS compared with two approved multikinase inhibitors for treatment of RET-mutant medullary thyroid cancer, according to the agent’s manufacturer.

News
August 02, 2023
2 min read
Save

Multifocal thyroid carcinoma less common in children, not linked to worse outcomes

Multifocal thyroid carcinoma less common in children, not linked to worse outcomes

Multifocal disease is not linked to a greater risk of recurrence or mortality for children and adolescents with papillary thyroid carcinoma, according to a study published in The Journal of Clinical Endocrinology & Metabolism.

News
July 31, 2023
2 min read
Save

Fracture risk lower for adults with hypoparathyroidism after thyroidectomy

Fracture risk lower for adults with hypoparathyroidism after thyroidectomy

Adults with postoperative hypoparathyroidism after thyroid cancer are less likely to sustain a fracture compared with those with preserved parathyroid function, according to findings published in the Journal of Bone and Mineral Research.

News
July 20, 2023
2 min read
Save

Levothyroxine during active surveillance of thyroid microcarcinoma may reduce tumor growth

Levothyroxine during active surveillance of thyroid microcarcinoma may reduce tumor growth

Levothyroxine therapy may help decrease tumor growth for adults with papillary thyroid microcarcinoma who are undergoing active surveillance, according to a study published in Thyroid.

News
June 05, 2023
3 min read
Save

Recurrence uncommon for adults with medullary thyroid microcarcinoma

Recurrence uncommon for adults with medullary thyroid microcarcinoma

In a small group of adults diagnosed with medullary thyroid microcarcinoma, few had disease recurrence or died during more than 6 years of follow-up, according to findings from an Australian database.

News
March 31, 2023
3 min read
Save

Hispanic and Asian adults with thyroid cancer have lower risk for death than white adults

Hispanic and Asian adults with thyroid cancer have lower risk for death than white adults

Hispanic and Asian adults diagnosed with thyroid cancer are more likely to have advanced disease, but also have better survival outcomes, compared with white adults, according to study data.

View more